Trial Profile
A Multicenter Comparative Randomized Double-blind Study of the Efficacy and Safety of BCD-057 (INN: Adalimumab, JSC BIOCAD, Russia) and Humira (INN: Adalimumab, Vetter Pharma) in Patients with Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Biocad
- 10 Jan 2020 Status changed from recruiting to completed.
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 25 Jun 2018 New trial record